A novel combination comprising a B-Raf inhibitor, particularly N-{3-[5-(2-Amino- 4-pyrimidinyl)-2-(l, 1 -dimethylethyl)- 1,3-thiazol-4-yl]-2-fluorophenyl} -2,6- difluorobenzenesulfonamide or a pharmaceutically acceptable salt thereof, and/or the MEK inhibitor N- {3-[3-cyclopropyl-5-(2-fluoro-4-iodo-phenylamino)6,8-dimethyl- 2,4,7- trioxo-3,4,6,7-tetrahydro-2H-pyrido[4,3-d]pyrimidin-l-yl]phenyl }acetamide, or a pharmaceutically acceptable salt or solvate thereof, and an EGFR inhibitor suitably cetuximab (Erbitux) or erlotinib pharmaceutical compositions comprising the same and methods of using such combinations and compositions in the treatment of conditions in which the inhibition of MEK and/or B-Raf and/or EGFR is beneficial, eg. cancer.Una combinación novedosa que comprende un inhibidor de B-Raf, particularmente N-{3-[5-(2-amino-4-pirimidinil)-2-(1,1-dimetiletil )-1,3-tiazol-4-il]-2-fluoro-fenil}-2,6-difluoro-bencen-sulfonamid a o una sal farmacéuticamente aceptable de la misma, y/o el inhibidor de MEK N-{3-[3-ciclopropil-5-(2-fluoro-4-yodo-fenil-amin o)-6,8-dimetil-2,4,7-trioxo-3,4,6,7-tetrahidro-2H-pirido-[4,3-d]- pirimidin-1-il]-fenil}acetamida, o una sal farmacéuticamente aceptable o solvato de la misma, y un inhibidor de EGFR, de forma adecuada cetuximab (Erbitux) o erlotinib composiciones farmacéuticas que los comprenden y métodos para utilizar dichas combinaciones y composiciones en el tratamiento de afecciones en las cuales sea beneficiosa la inhibición de MEK y/o B-Raf y/o EGFR, por ejemplo, el cáncer.
